MedTech Regulations
-
When Better Teams Make Slower Decisions
Leadership in Flow | Harun Rabbani, Precilium Last year, the regulatory submission went out late. Not because the science was weak. Not because the team lacked experience. But because three people believed they had authority over the final sign-off, and by the time that ambiguity was resolved, the window had narrowed. This year, the same…
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…
-
Why Good Boards Are Often Late to the Real Conversation
Most MedTech boards are not late because they are inattentive. They are late because they are responsible. That distinction matters more than it first appears. Boards exist to move organisations forward with confidence, not to reopen every decision once it has been prepared, reviewed, and presented. By the time something reaches the agenda, it is…
-
MHRA Proposes Indefinite Recognition of CE Marked Medical Devices in Great Britain
You did not build your company to spend its best energy navigating paperwork. You built it to move something that matters, a device, an idea, a breakthrough, from concept to clinic and from prototype to patient. The ambition has always been clear: to get life-saving products into the hands of clinicians efficiently, without unnecessary friction…
